Noninferiority and lopinavir/ritonavir monotherapy trials

被引：2

作者：

Pulido, Federico ^{[1
]}

Arribas, Jose R. ^{[2
]}

机构：

[1] Hosp Univ 12 Octubre, HIV Care Unit, Madrid, Spain

[2] Hosp Univ La Paz, HIV Care Unit, Madrid, Spain

来源：

AIDS | 2008年 / 22卷 / 13期

关键词：

D O I：

10.1097/QAD.0b013e32830a98ac

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1696 / 1697

页数：2

共 50 条

[31] The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration
Bierman, Wouter F. W.
van Vonderen, Marit G. A.
Veldkamp, Agnes I.
Burger, David M.
Danner, Sven A.
Reiss, Peter
van Agtmael, Michiel A.
ANTIVIRAL THERAPY, 2011, 16 (05) : 647 - 655
[32] Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
Delaugerre, Constance
Flandre, Philippe
Chaix, Marie Laure
Ghosn, Jade
Raffi, Francois
Dellamonica, Pierre
Jaeger, H.
Shuermann, D.
Cohen-Codar, Isabelle
Van, Philippe Ngo
Norton, Michael
Taburet, Anne-Marie
Delfraissy, Jean-Francois
Rouzioux, Christine
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) : 2934 - 2939
[33] Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
Gianotti, Nicola
Cozzi-Lepri, Alessandro
Antinori, Andrea
Castagna, Antonella
De Luca, Andrea
Celesia, Benedetto Maurizio
Galli, Massimo
Mussini, Cristina
Pinnetti, Carmela
Spagnuolo, Vincenzo
Monforte, Antonella d'Arminio
Ceccherini-Silberstein, Francesca
Andreoni, Massimo
PLOS ONE, 2017, 12 (02):
[34] Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting
Monforte, Antonella d'Arminio
Gianotti, Nicola
Cozzi-Lepri, Alessandro
Pinnetti, Carmela
Andreoni, Massimo
di Perri, Giovanni
Galli, Massimo
Poli, Andrea
Costantini, Andrea
Orofino, Giancarlo
Maggiolo, Franco
Mazzarello, Giovanni
Celesia, Benedetto Maurizio
Luciani, Filippo
Lazzarin, Adriano
Sighinolfi, Laura
Rizzardini, Giuliano
Bonfanti, Paolo
Perno, Carlo Federico
Antinori, Andrea
ANTIVIRAL THERAPY, 2014, 19 (03) : 319 - 324
[35] Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Pulido, Federico
Delgado, Rafael
Perez-Valero, Ignacio
Gonzalez-Garcia, Juan
Miralles, Pilar
Arranz, Alberto
Hernando, Asuncion
Arribas, Jose R.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (06) : 1359 - 1361
[36] HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
Sutherland, K. A.
Ghosn, J.
Gregson, J.
Mbisa, J. L.
Chaix, M. L.
Codar, I. Cohen
Delfraissy, J. F.
Delaugerre, C.
Gupta, R. K.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 243 - 248
[37] Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings
Matoga, Mitch M.
Hosseinipour, Mina C.
Aga, Evgenia
Ribaudo, Heather J.
Kumarasamy, Nagalingeswaran
Bartlett, John
Hughes, Michael D.
ANTIVIRAL THERAPY, 2017, 22 (03) : 205 - 213
[38] Lopinavir/Ritonavir: A Review for 2011
Teply, Robyn
Goodman, Mark
Destache, Christopher J.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 93 - 102
[39] The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients
Kandeel, Mahmoud
Morsy, Mohamed A. A.
Abd El-Lateef, Hany M. M.
Marzok, Mohamed
El-Beltagi, Hossam S. S.
Al Khodair, Khalid M. M.
Albokhadaim, Ibrahim
Venugopala, Katharigatta N. N.
PROCESSES, 2023, 11 (02)
[40] Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy
de Truchis, Pierre
Mathez, Dominique
Abe, Emuri
Dinh, Aurelien
LeDu, Damien
Greder-Belan, Alix
Alvarez, Jean-Claude
AIDS, 2010, 24 (08) : 1235 - 1236

← 1 2 3 4 5 →